David Ricks, CEO, Eli Lilly
Scott Mlyn | CNBC
Eli Lilly expects its experimental weight reduction pill will get approved as soon as early next yr, CEO David Ricks told Bloomberg TV on Monday.
The corporate is about to release key late-stage trial data on the drug, orforglipron, by the center of this yr.
Eli Lilly is pushing to get the pill to market because it competes with Novo Nordisk and smaller rivals for a significant share of the booming weight reduction drug market. Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy dominate the space, however the drugmakers and their competitors have been working to develop improved versions of the drugs.
Pills can be more convenient for patients than the present injectable forms. They might even be easier to fabricate at a time when Eli Lilly and Novo Nordisk have struggled to make enough drugs to maintain up with spiking demand.
Eli Lilly has said orforglipron helped patients lose as much as 14.7% of their weight in a mid-stage trial, compared with 2.3% amongst individuals who took a placebo.
Eli Lilly shares were trading about 2% lower on Monday.
